Scienture Regains Nasdaq Bid-Price Compliance; Q3 Revenue Jumps 256% to ~$1.22M
SCNX is trading near its 52-week low of $2.81 (3.9% above the low) on light trading volume (0.4× avg).
Summary
Scienture said Nasdaq closed its minimum bid-price deficiency after the stock held above $1.00 for ten sessions following the October 5 reverse split, removing delisting risk. The filing also repeats the October 13 preliminary Q3 revenue of ~$1.22M, up 256% sequentially.
Key Events · Corporate Governance and Compliance · SCNX
-
Nasdaq Compliance Regained
Nasdaq confirmed SCNX closed at or above $1.00 for the ten consecutive trading days from October 5 to October 16, 2026, and closed the minimum bid-price matter; the stock remains listed on Nasdaq.
-
Delisting Averted After Split
The company had received a Staff determination letter that it failed to regain compliance by the end of the second 180-day period on October 12, 2026; compliance followed the 1-for-25 reverse split effective October 5, 2026.
-
Q3 Revenue ~$1.22M
Preliminary unaudited Q3 2026 revenue of approximately $1.22 million, up 256% from ~$344,000 in Q2 2026, driven by the August 2026 REZENOPY launch and Arbli growth.
-
Arbli Units Up 74%
Arbli wholesale unit sales rose 74% sequentially, supported by formulary additions at three pediatric academic medical centers disclosed October 2, 2026.
Analysis · SCNX · Life Sciences
The listing risk that had hung over the stock is resolved: Nasdaq confirmed SCNX closed at or above $1.00 for ten straight sessions (Oct 5-16) and closed the matter, so the shares stay on Nasdaq. That matters because the company had already been told on October 12 it had failed to regain compliance at the end of its second 180-day window — the reversal came only after the 1-for-25 reverse split took effect October 5. The accompanying preliminary Q3 revenue of ~$1.22M (up 256% from Q2's ~$344K) is a restatement of the October 13 press release, not new information, but it confirms the second product (REZENOPY, launched August 2026) is contributing alongside Arbli's 74% sequential unit growth. Management targets profitability in 2027; the full Q3 10-Q will carry the audited detail.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNX was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $2.81 to $65.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.